2. Metabolic Enzyme/Protease Anti-infection NF-κB Immunology/Inflammation Protein Tyrosine Kinase/RTK JAK/STAT Signaling Epigenetics Stem Cell/Wnt Apoptosis Cell Cycle/DNA Damage
  3. Tyrosinase NADPH Oxidase HBV SARS-CoV Reactive Oxygen Species JAK STAT Apoptosis Caspase PARP
  4. Mulberrofuran G

Mulberrofuran G is a NOX inhibitor (IC50: 6.9 μM) and tyrosinase inhibitor. Mulberrofuran G exhibits anti-inflammatory, antioxidant, antiviral, antitumor, and neuroprotective effects. Mulberrofuran G can be used in the research of tumors, nervous system diseases, and other conditions.

For research use only. We do not sell to patients.

Mulberrofuran G Chemical Structure

Mulberrofuran G Chemical Structure

CAS No. : 87085-00-5

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Mulberrofuran G Related Antibodies

Top Publications Citing Use of Products

View All NADPH Oxidase Isoform Specific Products:

View All Isoforms
NOX1 NOX2 NOX4

View All JAK Isoform Specific Products:

View All Isoforms
JAK1 JAK2 JAK3 Tyk2 JAK

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All PARP Isoform Specific Products:

View All Isoforms
PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Mulberrofuran G is a NOX inhibitor (IC50: 6.9 μM) and tyrosinase inhibitor. Mulberrofuran G exhibits anti-inflammatory, antioxidant, antiviral, antitumor, and neuroprotective effects. Mulberrofuran G can be used in the research of tumors, nervous system diseases, and other conditions[1][2][3][4][5].

IC50 & Target[2][4]

NOX4

 

JAK2

 

STAT3

 

Caspase 3

 

Caspase-9

 

Cellular Effect
Cell Line Type Value Description References
Hep 3B2 IC50
> 30 μM
Compound: 6
Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay
Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay
[PMID: 19072214]
Hep 3B2 IC50
2.6 μM
Compound: 6
Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis
Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis
[PMID: 19072214]
Hep 3B2 IC50
28.6 μM
Compound: 6
Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA
Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA
[PMID: 19072214]
In Vitro

Mulberrofuran G (0.89-909.42 μM) inhibits HBV DNA replication in HepG 2.2.15 cells with an IC50 of 3.99 μM, and exhibits cytotoxicity to HepG 2.2.15 cells with a CC50 of 8.04 μM[1].
Mulberrofuran G (1-100 μM; 24 h) significantly suppresses cell proliferation, migration, and invasion in A549 and NCI-H226 cells, with the mechanism involving the inhibition of the JAK2/STAT3 pathway[2].
Mulberrofuran G (0-3 μM; 24 h) potently inhibits the infection of SARS-CoV-2 (βCoV/Korea/KCDC03/2020) in Vero cells, with an IC50 of 1.55 μM[3].
Mulberrofuran G (0.016-2 μM; 4-40 h) enhances cell viability, suppresses ROS production and apoptotic signals, and alleviates ER stress in oxygen-glucose deprivation/reoxygenation-treated SH-SY5Y cells. The mechanism is associated with the inhibition of NOX4[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mulberrofuran G Related Antibodies

Cell Viability Assay[2]

Cell Line: A549 cells and NCIH226 cells
Concentration: 1, 5, 10 and 100 μM
Incubation Time: 24 h
Result: Significantly inhibited the proliferation of lung cancer cells with IC50 values of 22.5 μM and 30.6 μM for A549 cells and NCIH226 cells, respectively.

Western Blot Analysis[4]

Cell Line: SH-SY5Y cells treated oxygen-glucose deprivation/reoxygenation (OGD/R)
Concentration: 0.08, 0.4, and 2 μM
Incubation Time: 40 h
Result: Inhibited the levels of cleaved caspase-9, caspase-3, and PARP.
In Vivo

Mulberrofuran G (0.2-5 mg/kg; intraperitoneal injection; single dose; 30 min before operation) exerts a protective effect in a rat model of middle cerebral artery occlusion/reperfusion[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (230-240 g) with middle cerebral artery occlusion/reperfusion (MCAO/R)[4]
Dosage: 0.2, 1 and 5 mg/kg
Administration: Intraperitoneal injection; single dose; 30 min before operation
Result: Significantly decreased the infarct volume in a dose-dependent manner, with the infarct volumes of 0.2, 1, and 5 mg/kg groups being 39.0%, 26.0%, and 19.0% respectively, compared to 51.2% in the vehicle group.
Downregulated the protein expression of NOX4, GRP78/BiP, p-IRE1α, XBP1, and CHOP in the ischemic brain tissue.
Molecular Weight

562.57

Formula

C34H26O8
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC1=C(C=CC(O)=C1)[C@]23[C@]4([H])[C@](C=C(C)C[C@@]4([H])C5=C(C=C(O)C=C5)O3)([H])C6=C(O)C=C(C7=CC8=C(C=C(O)C=C8)O7)C=C6O2
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (88.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7776 mL 8.8878 mL 17.7756 mL
5 mM 0.3555 mL 1.7776 mL 3.5551 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.25 mg/mL (2.22 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 1.25 mg/mL (2.22 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.84%

SDS (393 KB)

COA (251 KB) HNMR (320 KB) LCMS (267 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.7776 mL 8.8878 mL 17.7756 mL 44.4389 mL
5 mM 0.3555 mL 1.7776 mL 3.5551 mL 8.8878 mL
10 mM 0.1778 mL 0.8888 mL 1.7776 mL 4.4439 mL
15 mM 0.1185 mL 0.5925 mL 1.1850 mL 2.9626 mL
20 mM 0.0889 mL 0.4444 mL 0.8888 mL 2.2219 mL
25 mM 0.0711 mL 0.3555 mL 0.7110 mL 1.7776 mL
30 mM 0.0593 mL 0.2963 mL 0.5925 mL 1.4813 mL
40 mM 0.0444 mL 0.2222 mL 0.4444 mL 1.1110 mL
50 mM 0.0356 mL 0.1778 mL 0.3555 mL 0.8888 mL
60 mM 0.0296 mL 0.1481 mL 0.2963 mL 0.7406 mL
80 mM 0.0222 mL 0.1111 mL 0.2222 mL 0.5555 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Mulberrofuran G Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Mulberrofuran G87085-00-5TyrosinaseNADPH OxidaseHBVSARS-CoVReactive Oxygen SpeciesJAKSTATApoptosisCaspasePARPNOXHepatitis B virusSARS coronavirusJanus kinasepoly ADP ribose polymeraseMCAO/R modelHepG 2.2.15 cellsA549 cellsNCI-H226 cellsSARS-CoV-2,SH-SY5Y cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Mulberrofuran G
Cat. No.:
HY-N3239
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.